Anavex Life Sciences Corp (AVXL)

[Doktornolittle]

"will be a randomized, double blind, placebo-controlled study of ANAVEX 2-73 in patients with Rett syndrome lasting up to 12 weeks"

Many phase 2's are not double blind. The fact that this one is, is a very good thing if you believe Anavex 2-73 might really work. I think this is a big deal.

It is a fall-back if the (non orphan main population of) Alzheimer's path fizzles out, and it is potentially short term money to support a larger Alzheimer's trial if that path does not fizzle out. Approval on phase 2 is not super common, but this is an orphan disease and a double blind trial. That is the right combination for early approval.

A positive result would be fundamental validation of Anavex and Anavex 2-73 both. With an ongoing Ph 2/3 or 3 in Alzheimer's, Anavex would absolutely become a major league buyout target.